by Daniel W. Lee, Rebecca Gardner, David L. Porter, Chrystal U

Slides:



Advertisements
Similar presentations
Sepsis.
Advertisements

Lee DW III et al. Proc ASH 2013;Abstract 68.
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.
Maude et al. BLOOD, 25 JUNE 2015 x VOLUME 125, NUMBER 26
( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.
BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.
Disease modified Anti-rheumatic drugs ( DMARD)
United States Statistics on Sepsis
Characterization and treatment of chronic active Epstein- Barr virus disease: a 28-year experience in the United States by Jeffrey I. Cohen, Elaine S.
Multiple roles of the coagulation protease cascade during virus infection by Silvio Antoniak, and Nigel Mackman Blood Volume 123(17): April 24,
Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Fractionated Dosing Optimizes CAR T-Cell Therapy in Adult Relapsed/Refractory.
ELIANA: CTL019 Shows High CR Rate in Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell ALL New Findings in Hematology: Independent Conference.
Tips For the Bedside Nurse By: Jolene Staszek RN,BSN,OCN
CALS Instructor Update July 14, 2016
What does pharmacology have to do with treatment of heroin addiction?
STAT3 Michael Patel.
Professor John Gribben Barts Cancer Institute
Immunotherapy for lymphoma: The time is now
Nonengraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism  Gerald A. Colvin, David Berz, Muthalagu.
by Dai Chida, Osamu Miura, Akihiko Yoshimura, and Atsushi Miyajima
“Vitamin hypothesis”: explanation for allergy increase?
Selective expansion of polyfunctional pathogen-specific CD4+ T cells in HIV-1–infected patients with immune reconstitution inflammatory syndrome by Yolanda.
When monocyte life hangs by a thread
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Juvenile Myelomonocytic Leukemia
Figure 2 Three-step approach to the assessment and management
How I treat elderly patients with myeloma
by Malte Peters, Albrecht M. Müller, and Stefan Rose-John
Immunotherapy for Pediatric Cancer
Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.
SOX11 holds mantle cell lymphoma’s key to home
Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.
Diagnosis and management of anaphylaxis in precision medicine
NFAT control of innate immunity
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases.
Setting the table for macrophages
Immunomodulation in the critically ill
Role of IL-9 in the pathophysiology of allergic diseases
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Malignant Progenitors From Patients With Acute Myelogenous Leukemia Are Sensitive to a Diphtheria Toxin–Granulocyte-Macrophage Colony-Stimulating Factor.
Figure 1 Clinical case study
Volume 22, Issue 6, Pages (June 2014)
Anergy: the CLL cell limbo
by Anita Hill, Peter Hillmen, Stephen J
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Immunotherapy for acute lymphoblastic leukemia: from famine to feast
Pg and Ec LPS induced levels of soluble mediators from in cultures of individuals with and without T2D with periodontitis. Pg and Ec LPS induced levels.
Unstimulated levels of soluble mediators from in cultures of individuals with and without T2D with periodontitis. Unstimulated levels of soluble mediators.
by Dana T. Lounder, Qiong Bin, Cristina de Min, and Michael B. Jordan
Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets
Volume 155, Issue 2, Pages (February 2019)
by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A
Cytokine Signaling Modules in Inflammatory Responses
by Pamela J. Sung, Mayumi Sugita, Holly Koblish, Alexander E
Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient by Jian-Ping Zhang, Rui Zhang, Shih-Ting Tsao,
Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor.
Biology and treatment of Richter syndrome
PD-1 inhibition stimulates the proliferation and cytokine secretion of exhausted/senescent CD8+ T cells in vitro. PD-1 inhibition stimulates the proliferation.
A binding relationship with thrombin
CAR T cell immunotherapy for human cancer
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia by David L. Porter, Wei-Ting.
CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,
Schematic model illustrating how paracrine signaling drives LPS-stimulated cytokine secretion. Schematic model illustrating how paracrine signaling drives.
Fire behind the fury: IL-18 and MAS
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity by Benjamin L. Lampson, Siddha.
Cancer-associated pathways and biomarkers of venous thrombosis
by Jennifer N. Brudno, and James N. Kochenderfer
Peritonitis treatment algorithm.
Presentation transcript:

Current concepts in the diagnosis and management of cytokine release syndrome by Daniel W. Lee, Rebecca Gardner, David L. Porter, Chrystal U. Louis, Nabil Ahmed, Michael Jensen, Stephan A. Grupp, and Crystal L. Mackall Blood Volume 124(2):188-195 July 10, 2014 ©2014 by American Society of Hematology

IL-6 signaling and inhibition by tocilizumab. IL-6 signaling and inhibition by tocilizumab. (A) Classic IL-6 signaling restricted to IL-6R–expressing cells shown in pink (macrophages, neutrophils, T cells, and hepatocytes), which predominates when IL-6 levels are low. IL-6 binds to cell-associated IL-6R, leading to homodimerization of gp130 and initiation of downstream pathways. (B) Both classic and trans-IL-6 signaling, which occurs when IL-6 levels are elevated, leading to IL-6 signaling on a broad array of cells, because gp130 is ubiquitously expressed. Tocilizumab binding to both cell-associated IL-6R and soluble IL-6R inhibits classic and trans-signaling. IL-6R–expressing cells are shown in pink, whereas non-IL-6R–expressing cells are shown in blue. Daniel W. Lee et al. Blood 2014;124:188-195 ©2014 by American Society of Hematology

Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading system. The algorithm uses the revised grading system for CRS to direct clinical management for patients with immunotherapy-associated CRS. We recommend vigilant supportive care including empiric treatment of concurrent bacterial infections and maintenance of adequate hydration and blood pressure for every grade. Immunosuppression should be used in all patients with grade 3 or 4 CRS and instituted earlier in patients with extensive comorbidities or older age. Grades 2-4 organ toxicities are dictated by CTCAE v4.0. Daniel W. Lee et al. Blood 2014;124:188-195 ©2014 by American Society of Hematology

Cytokine changes associated with clinical findings in a hypothetical patient with grade 3 CRS. A dramatic rise in IL-6 and IFNγ levels is associated with the onset of fever at day 3 after CAR T-cell infusion. Cytokine changes associated with clinical findings in a hypothetical patient with grade 3 CRS. A dramatic rise in IL-6 and IFNγ levels is associated with the onset of fever at day 3 after CAR T-cell infusion. Despite vigilant supportive care, the patient becomes hypotensive, requiring the use of 1 vasopressor on day 5. After a brief period of cardiovascular stability, a second vasopressor is required to maintain adequate perfusion on day 6, at which time tocilizumab is administered. IL-6 levels continue to rise transiently after tocilizumab, because it continues to be produced and tocilizumab blocks IL-6R-mediated endocytosis. Vasopressor support is gradually weaned over the next 48 hours, although neurologic changes may persist or initially manifest after tocilizumab, but eventually resolve. Several other inflammatory cytokines, including TNFα, IL-2, GM-CSF, and others noted in the text are also likely to be elevated during the peak of the syndrome. Daniel W. Lee et al. Blood 2014;124:188-195 ©2014 by American Society of Hematology